Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Filgrastim biosimilar - Dong-A ST

Drug Profile

Filgrastim biosimilar - Dong-A ST

Alternative Names: DA 3030; Leucostim; Leukopoeitin - Dong-A ST; Leukostim®; rhG-CSF - Dong-A ST

Latest Information Update: 03 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Haematopoietic cell growth factor stimulants; Immunostimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic neuropathies

Highest Development Phases

  • Marketed Neutropenia
  • Phase II Diabetic neuropathies

Most Recent Events

  • 05 May 2016 Biocad plans a phase I trial for Leucocytosis (In volunteers) in Russia (SC) (NCT02762799)
  • 01 May 2016 Dong-A ST completes a phase I trial in Healthy male volunteers in South Korea (SC) (NCT02725086)
  • 01 Feb 2016 Dong-A ST initiates a phase I trial in Healthy male volunteers in South Korea (SC) (NCT02725086)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top